ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Stock Has Consensus Price Target of $98.00 According to Analysts

Key Points

• Analysts maintain a “Hold” consensus on ANI Pharmaceuticals, with five hold and three buy ratings and an average 12-month price target of $98.00 versus the stock’s $71.93 opening price.
• ANI Pharmaceuticals exceeded quarterly expectations, reporting $2.21 EPS and $266.04 million in revenue; revenue increased 25.8% year over year, while the company provided fiscal 2026 EPS guidance of $9.19–$9.69.
• Insiders sold 25,012 shares worth approximately $1.86 million during the last quarter, while institutional investors own 76.05% of the company; the stock remains near its 12-month low of $69.58.

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) has earned a consensus rating of "Hold" from the eight research firms that are covering the company, MarketBeat Ratings reports. Five research analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $98.00.

A number of brokerages have commented on ANIP. Weiss Ratings downgraded ANI Pharmaceuticals from a "buy (b-)" rating to a "hold (c+)" rating in a research note on Tuesday, August 11th. Guggenheim dropped their price target on ANI Pharmaceuticals from $124.00 to $119.00 and set a "buy" rating on the stock in a research report on Monday, August 10th. Oppenheimer started coverage on ANI Pharmaceuticals in a report on Wednesday, September 23rd. They issued a "market perform" rating and a $85.00 price target on the stock. Wall Street Zen downgraded ANI Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Saturday, August 8th. Finally, Canaccord Genuity Group dropped their target price on ANI Pharmaceuticals from $91.00 to $90.00 and set a "hold" rating on the stock in a research report on Monday, August 10th.

Insider Activity at ANI Pharmaceuticals

In other news, Director Jeanne Thoma sold 1,000 shares of the company's stock in a transaction dated Friday, September 11th. The shares were sold at an average price of $71.53, for a total transaction of $71,530.00. Following the completion of the transaction, the director owned 26,762 shares in the company, valued at approximately $1,914,285.86. This represents a 3.60% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Nikhil Lalwani sold 5,400 shares of the stock in a transaction dated Tuesday, September 15th. The stock was sold at an average price of $71.00, for a total transaction of $383,400.00. Following the completion of the sale, the chief executive officer directly owned 339,089 shares in the company, valued at approximately $24,075,319. This trade represents a 1.57% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 25,012 shares of company stock valued at $1,861,085. Company insiders own 8.10% of the company's stock.

Institutional Investors Weigh In On ANI Pharmaceuticals

Several large investors have recently made changes to their positions in ANIP. KBC Group NV acquired a new position in shares of ANI Pharmaceuticals during the first quarter worth approximately $28,000. Versant Capital Management Inc increased its position in ANI Pharmaceuticals by 103.3% in the 3rd quarter. Versant Capital Management Inc now owns 427 shares of the specialty pharmaceutical company's stock valued at $31,000 after acquiring an additional 217 shares during the period. Persistent Asset Partners Ltd bought a new stake in ANI Pharmaceuticals during the 2nd quarter valued at $76,000. State of Wyoming acquired a new position in ANI Pharmaceuticals during the 2nd quarter worth $86,000. Finally, Mill Creek Capital Advisors LLC acquired a new position in ANI Pharmaceuticals during the 4th quarter worth $213,000. Institutional investors and hedge funds own 76.05% of the company's stock.

ANI Pharmaceuticals Stock Performance

ANI Pharmaceuticals stock opened at $71.93 on Thursday. The company has a debt-to-equity ratio of 0.99, a current ratio of 2.91 and a quick ratio of 2.41. ANI Pharmaceuticals has a 12 month low of $69.58 and a 12 month high of $97.00. The company has a fifty day moving average price of $74.68 and a two-hundred day moving average price of $78.08. The company has a market cap of $1.65 billion, a PE ratio of 15.50, a P/E/G ratio of 2.30 and a beta of 0.50.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last issued its earnings results on Friday, August 7th. The specialty pharmaceutical company reported $2.21 earnings per share for the quarter, topping analysts' consensus estimates of $2.04 by $0.17. ANI Pharmaceuticals had a net margin of 11.07% and a return on equity of 27.37%. The company had revenue of $266.04 million for the quarter, compared to analysts' expectations of $260.13 million. During the same period in the prior year, the company earned $1.80 earnings per share. The firm's revenue was up 25.8% compared to the same quarter last year. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. Research analysts expect that ANI Pharmaceuticals will post 7.76 earnings per share for the current year.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a specialty pharmaceutical company that develops, manufactures and commercializes branded and generic prescription medicines. The company focuses on products with complex formulations, difficult-to-manufacture dosage forms and limited competition, serving therapeutic areas that include rare diseases, ophthalmology, endocrinology, central nervous system conditions and other specialty markets.

ANI's portfolio includes Cortrophin Gel (repository corticotropin injection), a specialty therapy used for certain inflammatory and autoimmune conditions, as well as a range of established brand and generic products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.